A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Morris, Michael J.
Wong, Jeffrey Y. C.
Nordquist, Luke
Szmulewitz, Russell Zelig
Agarwal, Neeraj
Attiyeh, Edward F.
Max, Steven I.
Divgi, Chaitanya R.
Patricia, Daniel
Cao, Yu
Li, Xiang
Yu, Alex
Urtishak, Karen
Lauring, Josh David
Sartor, Oliver
机构：
[1] Mem Sloan Kettering Canc Ctr, Div Solid Tumor Oncol, New York, NY 10021 USA
[2] City Hope Natl Med Ctr, Dept Radiat Oncol, 1500 E Duarte Rd, Duarte, CA 91010 USA
[3] XCanc Omaha, Omaha, NE USA
[4] Univ Chicago, Dept Med, Sect Hematol Oncol, Chicago, IL 60637 USA
[5] Huntsman Canc Inst, Salt Lake City, UT USA
[6] Janssen Res & Dev LLC, Spring House, PA USA
[7] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5010
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase (Ph) 1b/2 study of ribociclib (R) in combination with docetaxel (D) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).
    de Kouchkovsky, Ivan
    Rao, Arpit
    Carneiro, Benedito A.
    Zhang, Li
    Lewis, Catriona
    Phone, Audrey
    Small, Eric Jay
    Friedlander, Terence W.
    Fong, Lawrence
    Paris, Pamela
    Ryan, Charles J.
    Szmulewitz, Russell Zelig
    Aggarwal, Rahul Raj
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
    Kenneth J. Pienta
    Jean-Pascal Machiels
    Dirk Schrijvers
    Boris Alekseev
    Mikhail Shkolnik
    Simon J. Crabb
    Susan Li
    Shobha Seetharam
    Thomas A. Puchalski
    Chris Takimoto
    Yusri Elsayed
    Fitzroy Dawkins
    Johann S. de Bono
    Investigational New Drugs, 2013, 31 : 760 - 768
  • [23] Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
    Pienta, Kenneth J.
    Machiels, Jean-Pascal
    Schrijvers, Dirk
    Alekseev, Boris
    Shkolnik, Mikhail
    Crabb, Simon J.
    Li, Susan
    Seetharam, Shobha
    Puchalski, Thomas A.
    Takimoto, Chris
    Elsayed, Yusri
    Dawkins, Fitzroy
    de Bono, Johann S.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (03) : 760 - 768
  • [24] Updated biomarker results from a phase 1/2 study of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE).
    Mckay, Rana R.
    Xie, Wanling
    Ajmera, Archana
    Saraiya, Biren
    Parikh, Mamta
    Folefac, Edmund
    Olson, Adam C.
    Heath, Elisabeth I.
    Parikh, Rahul Atul
    Ivy, S. Percy
    Mendel, Eliezer
    Allen, Van
    Lindeman, Neal Ian
    Shapiro, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [25] A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC)
    Sharp, Adam
    Bernard-Tessier, Alice
    Borchiellini, Delphine
    de Bono, Johann
    Fizazi, Karim
    Gravis, Gwenaelle
    Lorente, David
    Mahammedi, Hakim
    Mellado, Begona
    Olmos, David
    Pacey, Simon
    Piulats, Jose
    Ramirez, Sara P.
    Gorbatchevsky, Igor
    Heath, Elisabeth
    CANCER RESEARCH, 2024, 84 (07)
  • [26] A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC)
    Heath, Elisabeth I.
    Sharp, Adam
    Borchiellini, Delphine
    De Bono, Johann S.
    Fizazi, Karim
    Gravis, Gwenaelle
    Lorente, David
    Mahammedi, Hakim
    Mellado-Gonzalez, Bego Na
    Olmos, David
    Pacey, Simon
    Piulats, Josep M.
    Ramirez, Sara Perez
    Gorbatchevsky, Igor
    Bernard-Tessier, Alice
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Preliminary results from a phase 1/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Stein, Mark N.
    Zhang, Jingsong
    Kelly, William Kevin
    Wise, David R.
    Tsao, Kai
    Carneiro, Benedito A.
    Falchook, Gerald Steven
    Sun, Furong
    Govindraj, Shilpa
    Sims, Jennifer S.
    Zhu, Min
    Seebach, Frank A.
    Lowy, Israel
    Thanigaimani, Pradeep
    Sandigursky, Sabina
    Miller, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [28] A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).
    Petrylak, Daniel Peter
    Vogelzang, Nicholas J.
    Chatta, Gurkamal S.
    Fleming, Mark T.
    Smith, David C.
    Appleman, Leonard Joseph
    Hussain, Arif
    Modiano, Manuel
    Singh, Parminder
    Tagawa, Scott T.
    Gore, Ira
    McClay, Edward Francis
    Mega, Anthony E.
    Sartor, A. Oliver
    Somer, Bradley G.
    Wadlow, Raymond Couric
    Shore, Neal D.
    Stambler, Nancy
    DiPippo, Vincent A.
    Israel, Robert Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [29] CYCLONE 1: A phase 2 study of abemaciclib in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a novel hormonal agent and taxane-based chemotherapy.
    Agarwal, Neeraj
    Oudard, Stephane
    Piulats, Josep M.
    Schweizer, Michael Thomas
    Flechon, Aude
    Gordoa, Teresa Alonso
    Nacerddine, Karim
    Lithio, Andrew
    Johnston, Erica L.
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer
    Kelly, William Kevin
    Thanigaimani, Pradeep
    Sun, Furong
    Seebach, Frank A.
    Lowy, Israel
    Sandigursky, Sabina
    Miller, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345